Gastric electrical stimulation versus per-oral pyloromyotomy for the treatment of nausea and vomiting associated with gastroparesis: An observational study of two cohorts.

chronic nausea and vomiting syndrome gastric electrical stimulation gastric emptying gastroparesis peroral endoscopic pyloromyotomy

Journal

Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572

Informations de publication

Date de publication:
07 2023
Historique:
revised: 21 02 2023
received: 10 06 2022
accepted: 10 03 2023
medline: 14 6 2023
pubmed: 25 3 2023
entrez: 24 3 2023
Statut: ppublish

Résumé

Both gastric electrical stimulation (GES) and gastric-peroral endoscopic myotomy (G-POEM) can be offered to patients with gastroparesis and predominant nausea and vomiting. The study's aim was to compare GES and G-POEM efficacy on nausea and vomiting scores in patients with gastroparesis. Two multicenter cohorts of patients with medically refractory gastroparesis with predominant nausea and vomiting (defined as a score >2 on nausea and vomiting subscale that varied from 0 to 4) were treated either with GES (n = 34) or G-POEM (n = 30) and were followed for 24 months (M). Clinical response was defined as a decrease of ≥1 point in nausea and vomiting subscale without premature exclusion due to switch from one to the other technique before M24. Changes in symptomatic scales and quality of life were also monitored. Patients from both groups were comparable although the mean score of nausea and vomiting subscale was higher in GES (3.0) compared to G-POEM group (2.6; p = 0.01). At M24, clinical response was achieved in 21/34 (61.7%) patients with GES and in 21/30 (70.0%; p = 0.60) patients with G-POEM. Mean scores of nausea and vomiting subscale decreased at M24 in both GES (from 3.0 to 1.6; p < 0.001) and G-POEM (from 2.6 to 1.2; p < 0.001) groups, although there was no difference between groups (difference adjusted from baseline: -0.28 [-0.77; 0.19]; p = 0.24). Likewise, symptomatic and quality of life scores improved at M24 in both groups, without difference according to treatment group. At M24, we did not observe significant difference in efficacy of GES and G-POEM in medically refractory gastroparesis with predominant nausea and vomiting.

Sections du résumé

BACKGROUND
Both gastric electrical stimulation (GES) and gastric-peroral endoscopic myotomy (G-POEM) can be offered to patients with gastroparesis and predominant nausea and vomiting. The study's aim was to compare GES and G-POEM efficacy on nausea and vomiting scores in patients with gastroparesis.
METHODS
Two multicenter cohorts of patients with medically refractory gastroparesis with predominant nausea and vomiting (defined as a score >2 on nausea and vomiting subscale that varied from 0 to 4) were treated either with GES (n = 34) or G-POEM (n = 30) and were followed for 24 months (M). Clinical response was defined as a decrease of ≥1 point in nausea and vomiting subscale without premature exclusion due to switch from one to the other technique before M24. Changes in symptomatic scales and quality of life were also monitored.
KEY RESULTS
Patients from both groups were comparable although the mean score of nausea and vomiting subscale was higher in GES (3.0) compared to G-POEM group (2.6; p = 0.01). At M24, clinical response was achieved in 21/34 (61.7%) patients with GES and in 21/30 (70.0%; p = 0.60) patients with G-POEM. Mean scores of nausea and vomiting subscale decreased at M24 in both GES (from 3.0 to 1.6; p < 0.001) and G-POEM (from 2.6 to 1.2; p < 0.001) groups, although there was no difference between groups (difference adjusted from baseline: -0.28 [-0.77; 0.19]; p = 0.24). Likewise, symptomatic and quality of life scores improved at M24 in both groups, without difference according to treatment group.
CONCLUSIONS AND INFERENCES
At M24, we did not observe significant difference in efficacy of GES and G-POEM in medically refractory gastroparesis with predominant nausea and vomiting.

Identifiants

pubmed: 36961085
doi: 10.1111/nmo.14565
doi:

Types de publication

Observational Study Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14565

Informations de copyright

© 2023 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.

Références

Schol J, Wauters L, Dickman R, et al. United European gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2021;9:287-306.
Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex body mass symptom onset delay in gastric emptying and gastroparesis severity. Gastroenterology. 2011;140:101-115.
Hasler WL, Wilson LA, Parkman HP, et al. Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil. 2013;25:427-438.
Parkman HP, Hallinan EK, Hasler WL, et al. Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil. 2016;28:1902-1914.
Gourcerol G, Coffin B, Bonaz B, et al. Impact of gastric electrical etimulation on economic burden of refractory vomiting: a french nationwide multicentre study. Clin Gastroenterol Hepatol. 2022;20(8):1857-1866.e1.
Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology. 2015;149:1762-1774.
Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125:421-428.
Hedjoudje A, Huet E, Leroi AM, Desprez C, Melchior C, Gourcerol G. Efficacy of gastric electrical stimulation in intractable nausea and vomiting at 10 years: a retrospective analysis of prospectively collected data. Neurogastroenterol Motil. 2020;32:e13949.
McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol. 2011;9:314-319.
Abell TL, Yamada G, McCallum RW, et al. Effectiveness of gastricelectrical stimulation in gastroparesis: results from a large prospectively collected database of national gastroparesis registries. Neurogastroenterol Motil. 2019;31:e13714.
Ducrotte P, Coffin B, Bonaz B, et al. Gastric electrical stimulation reduces refractory vomiting in a randomized crossover trial. Gastroenterology. 2020;158:506-514.
Jacques J, Pagnon L, Hure F, et al. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. Endoscopy. 2019;51:40-49.
Vosoughi K, Ichkhanian Y, Benias P, et al. Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial. Gut. 2022;71:25-33.
Gregor L, Wo J, DeWitt J, et al. Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a prospective single-center experience with mid-term follow-up. Gastrointest Endosc. 2021;94:35-44.
Labonde A, Lades G, Debourdeau A, et al. Gastric peroral endoscopic myotomy in refractory gastroparesis: long-term outcomes and predictive score to improve patient selection. Gastrointest Endosc. 2022;96:500-508. doi:10.1016/j.gie.2022.04.002
Abdelfatah MM, Noll A, Kapil N, et al. Long-term outcome of gastric per-oral endoscopic pyloromyotomy in treatment of gastroparesis. Clin Gastroenterol Hepatol. 2021;19:816-824.
Kamal F, Khan MA, Lee-Smith W, et al. Systematic review with meta- analysis: one-year outcomes of gastric peroral endoscopic myotomy for refractory gastroparesis. Aliment Pharmacol Ther. 2022;55:168-177.
Martinek J, Hustak R, Mares J, et al. Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial. Gut. 2022;71:2170-2178. doi:10.1136/gutjnl-2022-326904
Shen S, Luo H, Vachaparambil C, et al. Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long term outcomes. Endoscopy. 2020;52:349-358.
Slim K, Bousquet J, Kwiatkowski F, Lescure G, Pezet D, Chipponi J. First validation of the French version of the gastrointestinal quality of life index (GIQLI). Gastroenterol Clin Biol. 1999;23:25-31.
Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the gastroparesis cardinal symptom index. Aliment Pharmacol Ther. 2003;18:141-150.
Gourcerol G, Melchior C, Wuestenberghs F, et al. Delayed gastric emptying as an independent predictor of mortality in gastroparesis. Aliment Pharmacol Ther. 2022;55:867-875.
Ye Y, Jiang B, Manne S, et al. Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. Gut. 2021;70:644-653.
Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225-1233.
Navas CM, Crowell MD, Lacy BE. The willingness of patients with gastroparesis to take risks with medications. Aliment Pharmacol Ther. 2019;49:429-436.
Zoll B, Jehangir A, Edwards MA, et al. Surgical treatment for refractory gastroparesis: stimulator, pyloric surgery or both? J Gastrointest Surg. 2020;24:2204-2211.
Marowski S, Xu Y, Greenberg JA, Funk LM, Lidor AO, Shada AL. Both gastric electrical stimulation and pyloric surgery offer long-term symptom improvement in patients with gastroparesis. Surg Endosc. 2021;35:4794-4804.
Wuestenberghs F, Juge M, Melchior C, Desprez C, Leroi AM, Gourcerol G. Association between symptoms, quality of life, and gastric emptying in dyspeptic patients. J Neurogastroenterol Motil. 2019;25:534-543.
Vijayvargiya P, Camilleri M, Chedid V, Mandawat A, Erwin PJ, Murad MH. Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. Gastroenterology. 2019;156:1650-1660.
Tack J, Goelen N, Carbone F, et al. Prokinetic effects and symptom relief in the pharmacotherapy of gastroparesis. Gastroenterology. 2020;158:1841-1842.
Talley NJ, Locke GR 3rd, Lahr BD, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut. 2006;55:933-939.
Wuestenberghs F, Gourcerol G. Editorial: on the road towards treatment of gastroparesis-accelerating but do we get closer? Aliment Pharmacol Ther. 2021;54:183-184.
McCallum RW, Dusing RW, Sarosiek I, Cocjin J, Forster J, Lin Z. Mechanisms of symptomatic improvement after gastric electrical stimulation in gastroparetic patients. Neurogastroenterol Motil. 2010;22:161-167.
Ouelaa W, Ghouzali I, Langlois L, et al. Gastric electrical stimulation decreases gastric distension-induced central nociception response through direct action on primary afferents. PLoS One. 2012;7:e47849.
Gourcerol G, Ouelaa W, Huet E, Leroi AM, Ducrotte P. Gastric electrical stimulation increases the discomfort threshold to gastric distension. Eur J Gastroenterol Hepatol. 2013;25:213-217.
Lin Z, Forster J, Sarosiek I, McCallum RW. Effect of high-frequency gastric electrical stimulation on gastric myoelectric activity in gastroparetic patients. Neurogastroenterol Motil. 2004;16:205-212.
Gourcerol G, Chaput U, LeBlanc I, et al. Gastric electrical stimulation in intractable nausea and vomiting: assessment of predictive factors of favorable outcomes. J Am Coll Surg. 2009;209:215-221.
Gourcerol G, Leblanc I, Leroi AM, Denis P, Ducrotte P. Gastric electrical stimulation in medically refractory nausea and vomiting. Eur J Gastroenterol Hepatol. 2007;19:29-35.
Soliman H, Gourcerol G. Gastric electrical stimulation: role and clinical impact on chronic nausea and vomiting. Front Neurosci. 2022;16:909149.
Soliman H, Gourcerol G. Targeting the pylorus in gastroparesis: from physiology to endoscopic pyloromyotomy. Neurogastroenterol Motil. 2023;35:e14529. doi:10.1111/nmo.14529
Vosoughi K, Ichkhanian Y, Jacques J, et al. Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy. Gastrointest Endosc. 2020;91:1289-1299.
Watts LS, Baker JR, Lee AA, et al. Impact of gastric per-oral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients. Neurogastroenterol Motil. 2020;32:e13892.
Attaar M, Su B, Wong HJ, et al. Significant changes in impedance planimetry (EndoFLIP) measurements after peroral pyloromyotomy for delayed gastric emptying. Surg Endosc. 2022;36:1536-1543.
Wuestenberghs F, Gourcerol G. Pyloric distensibility in health and disease. Am J Physiol Gastrointest Liver Physiol. 2021;321:G133-G138.
Davis BR, Sarosiek I, Bashashati M, Alvarado B, McCallum RW. The long-term efficacy and safety of pyloroplasty combined with gastric electrical stimulation therapy in gastroparesis. J Gastrointest Surg. 2017;21:222-227.
Strong AT, Rodriguez J, Kroh M, Ponsky J, Cline M, El-Hayek K. Safety and feasibility of per-Oral pyloromyotomy as augmentative therapy after prior gastric electrical stimulation for gastroparesis. J Am Coll Surg. 2019;229:589-595.

Auteurs

Guillaume Gourcerol (G)

Physiology and Gastroenterology Department, INSERM 1073-CIC 1404, RouenUniversity Hospital, Rouen, France.

Jean Michel Gonzalez (JM)

Gastroenterology Department, North Hospital AP-HM, Marseille, France.

Bruno Bonaz (B)

Gastroenterology Department CHU, Grenoble, France.

Sébastien Fontaine (S)

Diabetology Department CHU, Toulouse, France.

Frank Zerbib (F)

Gastroenterology Department, Centre Medico-chirurgical Magellan, INSERM CIC 1401, CHU de Bordeaux, Hôpital Haut-Lévêque, Université de Bordeaux, Bordeaux, France.

Francois Mion (F)

Physiology Department HCL, Lyon, France.

Paul Basile (P)

Physiology and Gastroenterology Department, INSERM 1073-CIC 1404, RouenUniversity Hospital, Rouen, France.

André Gillibert (A)

Biostatistic Department, Rouen University Hospital, Rouen, France.

Amélie Labonde (A)

CHU, Limoges, France.

Heithem Soliman (H)

Gastroenterology Department, Université de Paris, AP-HP, Hopital Louis Mourier, DMU ESPRIT, Colombes, France.

Véronique Vitton (V)

Gastroenterology Department, North Hospital AP-HM, Marseille, France.

Benoit Coffin (B)

Gastroenterology Department, Université de Paris, AP-HP, Hopital Louis Mourier, DMU ESPRIT, Colombes, France.

Jérémie Jacques (J)

CHU, Limoges, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH